AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Novavax Announces Positive Phase 3 Trial Results for COVID-19 and Influenza Vaccine Candidates.
ByAinvest
Thursday, Jun 12, 2025 12:21 am ET1min read
Novavax Inc (NVAX) announced promising Phase 3 trial results for its COVID-19 and influenza vaccine candidates. Both vaccines induced robust immune responses comparable to licensed vaccines and were well tolerated. No new safety concerns were observed, and the company is actively seeking partnerships to further develop these programs.
Novavax Inc (NVAX) recently announced promising results from its Phase 3 trial for its COVID-19 and influenza vaccine candidates. The trial demonstrated robust immune responses comparable to licensed vaccines and was well tolerated, with no new safety concerns observed. The company is actively seeking partnerships to further develop these programs.The Phase 3 trial, which included approximately 2,000 adults aged 65 and older, showed that both the COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccine candidates induced immune responses similar to Nuvaxovid® and Fluzone HD, respectively. The trial also found that both vaccines were well tolerated, with reactogenicity comparable to authorized comparators and nearly all (98%) solicited adverse events being mild or moderate in severity.
Analysts from BTIG noted that the primary objective of the trial was to confirm that both vaccines' immunogenic effectiveness falls within a protective range while showing minimal interference between the two. The initial data indicated satisfactory results, meeting expectations [1].
Based on the consensus recommendation from 7 brokerage firms, Novavax Inc's average brokerage recommendation is currently 2.3, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies a Strong Buy, and 5 denotes a Sell [1].
The company is actively pursuing new partnerships and collaborations, including an expanded agreement with Takeda for the Japanese market. However, Novavax Inc is still awaiting FDA approval for its COVID-19 vaccine BLA and has not yet secured a partner for the development and commercialization of its latest COVID-influenza combination vaccine [1].
References:
[1] https://www.gurufocus.com/news/2922217/novavax-nvax-phase-3-trial-shows-promising-results-in-vaccine-study-nvax-stock-news
[2] https://www.biospace.com/press-releases/novavaxs-covid-19-influenza-combination-and-stand-alone-influenza-vaccine-candidates-showed-robust-immune-responses-and-were-well-tolerated-in-initial-cohort-of-a-phase-3-trial
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet